Onconetix (ONCO) Net Equity Issued and Repurchased (2022 - 2025)

Onconetix (ONCO) posted quarterly Net Equity Issued and Repurchased of $21.0 for Q4 2025, up 200.0% quarter-over-quarter from -$21.0 in Q3 2025.

Onconetix (ONCO) Net Equity Issued and Repurchased (2022 - 2025) Analysis & Trends

Onconetix (ONCO) has reported Net Equity Issued and Repurchased for 2 consecutive years, with $21.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $21.0; the TTM figure through Dec 2025 stood at $6.4 million (changed N/A YoY), while the FY2025 annual figure was $6.4 million, up 592.68% from the prior year.
Net Equity Issued and Repurchased rose to $21.0 in Q4 2025 per ONCO's latest filing, from -$21.0 in the prior quarter.
Across five years, Net Equity Issued and Repurchased topped out at $9.1 million in Q3 2022 and bottomed at -$21.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Onconetix	1.44 Mn	-4.50 Mn	4,303.00	-

Download Data